Location Greater Boston Area, United States, North America Regions East Coast, New England Gender Male
LinkedIn View on LinkedIn
Robert Discordia, Ph.D., joined Corbus in May 2018. Dr. Discordia brings to Corbus more than 25 years of biopharmaceutical industry experience in CMC development and business operations. Prior to joining the Company, Dr. Discordia was Executive Director, Business Operations and Procurement for Global Product Development & Supply at
Bristol-Myers Squibb. While serving in that position, he was responsible for managing the strategic business partnerships for the company's small molecule development and commercial manufacturing. He oversaw approximately 55 employees at seven sites and $700 million in annual spend. Prior to that, he served as Bristol-Myers Squibb's Group Director & Head, External Partner Management, Pharmaceutical Development. In this capacity, he developed and led the organization, overseeing third-party providers of development services and clinical manufacturing for Bristol-Myers Squibb. Over his career, he had leadership roles in the CMC development and launch of multiple medicines, including TAXOL®, BARACLUDE® and ELIQUIS®. He currently serves on the Advisory Board for the Drug, Chemical & Associated Technologies Association (DCAT) and is a member of the Outsourced Pharma Editorial Advisory Board. Dr. Discordia received his Ph.D. in Organic Chemistry from Syracuse University and a Bachelor of Science in Chemistry from SUNY Cortland. He completed his postdoctoral training at The Research Institute of Scripps Clinic and the University of California, San Diego in the laboratory of Professor K. C. Nicolaou.
